{
    "nctId": "NCT01550848",
    "briefTitle": "A Phase II Study of Abraxane Gemcitabine Combination in Patients With Metastatic Breast Cancer",
    "officialTitle": "A Phase II Study of Abraxane Combined With Gemcitabine in the Patients With Metastatic Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Metastatic Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 84,
    "primaryOutcomeMeasure": "overall response rate",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Female between 18 and 70 years old;\n* Patients with histologic proved metastatic breast cancer, unsuitable to be treated with surgery;\n* ECOG (Eastern Cooperative Oncology Group) 0\\~1;\n* Normal functions with heart, liver,renal and bone marrow:WBC\u22653.5\u00d7109/L\uff1bHb\u226590 g/L\uff1bplt\u2265100\u00d7109/L;\n* Got ICF (Informed Consent Form) before enrollment;\n* Life expectancy more than 12 weeks\n\nExclusion Criteria:\n\n* Pregnant or breast-feeding women or positive serum pregnancy test;\n* Uncontrolled brain metastases. Patients with brain metastases must be locally treated and the disease must be stable for at least one month at the time of enrolling;\n* Participation in any investigational drug study within 4 weeks preceding treatment start;\n* Concurrent other malignancy at other sites or previous other cancer within the last 5 years, with the exception of adequately treated in situ carcinoma of cervix uteri or basal or squamous cell carcinoma of the skin or a contralateral breast cancer;\n* Serious uncontrolled intercurrent infections;\n* Poor compliance",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}